Lindus Health launches Cardiovascular CRO offering.
READ MORE
The digital therapeutics (DTx) market sets the stage for a future where healthcare is more accessible, personalized, and efficient. This unique sector of medicine is poised to redefine the boundaries of medicine, blending technology with traditional health care to manage chronic diseases and other medical conditions. This blog will explore the predictions shaping the future of the digital therapeutics market, from the surge in market value and the focus on chronic disease management to the pivotal role of software solutions as FDA-approved medical interventions.
Digital therapeutics (DTx), are evidence-based software interventions to treat medical conditions. These therapies are FDA-approved and exist in the form of web-based applications, mobile phone applications, wearable devices, and more.
DTx products have grown in prevalence in recent years as they greatly transform the way people receive their health care. By delivering medical interventions through software (computers, smartphones, and other technologies), digital therapeutics enable patients to have increased access to essential therapies, convenience in healthcare delivery, real-time and tailored feedback from healthcare providers, and more.
Non-pharmaceutical interventions highlight the growing recognition of the multidimensional nature of chronic illnesses and the need for comprehensive, individualized treatment plans. They reflect a shift towards empowering patients to take an active role in their health management, emphasizing the importance of addressing physical, psychological, and social factors in the health and wellness journey.
With increasing popularity in non-pharmaceutical medical interventions such as lifestyle modifications, behavioral therapies, and alternative medicine, DTx products have obtained widespread credibility to treat a wide array of chronic conditions. For example, Irritable Bowel Syndrome, one of the most common GI disorders among adults, is largely influenced by overall mental health. Digital therapies for this indication often utilize cognitive behavioral therapy (CBT) techniques among other psychological treatments to improve mental health and ultimately IBS symptoms.
The COVID-19 pandemic has significantly influenced the popularity and acceptance of DTx products, serving as a catalyst for their rapid growth and integration into healthcare systems. With the pandemic enforcing social distancing and minimizing in-person medical consultations, digital therapeutics emerged as a crucial solution for continuing treatment, especially for conditions like mental health, psychiatric disorders, and cognitive impairments, which saw an increased mainstream focus due to pandemic-induced distress.
The shift towards digital solutions allowed for more accessible, personalized, and engaging healthcare options that could be conveniently used from home, thereby meeting the newfound patient expectations for control, flexibility, and seamless integration into their daily lives.
All of the factors mentioned before underscore the value of digital therapeutics as an integral component of modern healthcare, but what does the future hold for this industry? Below are some predictions we have for the DTx market in 2024.
The DTx market is expected to witness substantial growth. In 2023, the market size was valued anywhere between $4-7 billion USD. This year, it is anticipated that the DTx market will reach $10.1 billion USD, further emphasizing the efficacy and popularity of these innovative interventions.
The prevalence of chronic diseases like diabetes, cardiovascular diseases, and mental health disorders is a major driver for the digital therapeutics market.
Diabetes, in particular, is expected to dominate the market due to the rising need for customized solutions and the growing prevalence of the condition globally. DTx products for diabetes can incorporate personalized nutrition and exercise plans, mental health support, glucose monitoring and other techniques that enable individuals of this patient population to take control of their health by incorporating lifestyle modifications on their own.
North America currently leads and will continue to lead the DTx market in 2024, but the Asia-Pacific region is expected to witness the fastest growth rate this year. This is due to factors such as increased government spending on healthcare, increased prevalence of smartphones and other technologies, and a growing demand for efficient healthcare IT systems.
Regulatory bodies of Australia, Japan, Singapore, South Korea, and more have welcomed the adoption of these interventions into their frameworks as more and more data supporting their effectiveness becomes available. Additionally, with the growing incidence of diabetes and other chronic diseases, the need for remote patient-monitoring is becoming all the more pertinent.
While artificial intelligence (AI) in the context of clinical research and healthcare has been in experimental phases for some time now, it is expected to move to more real-world applications. AI will also continue to be explored for more complex use cases requiring further testing and development, such as assimilating information from diverse sources like medical images, clinical reports, and voice data.
With the robust amount of personal data DTx products collect, there is evident concern regarding security and privacy that the market faces going forward. Providers of these innovative technologies need to be extremely vigilant in ensuring personal health information (PHI) is not compromised, especially when being transferred across multiple systems. It’s possible tha by adopting a unified technology platform to manage clinical research and patient data in DTx products that the likelihood of breaches decreases.
The FDA is adapting to the growing significance of digital health technologies, including AI and machine learning (ML), virtual reality (VR), digital therapeutics, wearables, and software in healthcare. The agency plans to establish a new digital health advisory committee fully operational by 2024, expected to provide insights on a wide range of technologies in efforts to improve health equity.
In efforts to become more profitable, DTx companies may focus on the development of technologies that do not require FDA approval. This in turn would make these innovative products more accessible to patient populations, especially those who lack adequate health insurance.
As we look ahead to the rest of this year, the DTx market should only continue to grow. The predictions for this dynamic sector foreshadow a future where digital therapeutics not only becomes more ingrained in our healthcare systems but also plays a pivotal role in reshaping patient care and treatment modalities across the globe. With the challenges and opportunities presented by regulatory landscapes, cybersecurity threats, and the integration of AI and wearable technology, the trajectory of digital therapeutics is undeniably upward.
